UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)

Clinical infectious diseases, 2015-05, Vol.60 (10), p.1462-1471

2015

Volltextzugriff (PDF)

Pharmacokinetics and Safety of Intravenous Ceftolozane-Tazobactam in Healthy Adult Subjects following Single and Multiple Ascending Doses

Antimicrobial Agents and Chemotherapy, 2012-06, Vol.56 (6), p.3086-3091

2012

Volltextzugriff (PDF)

Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy

The Annals of pharmacotherapy, 2009-07, Vol.43 (7), p.1211-1219

2009

Volltextzugriff (PDF)

Thrombocytopenia Associated with Linezolid Therapy

Clinical infectious diseases, 2002-03, Vol.34 (5), p.695-698

2002

Volltextzugriff (PDF)

Quinupristin-Dalfopristin Resistance in Gram-Positive Bacteria: Mechanism of Resistance and Epidemiology

Clinical infectious diseases, 2004-01, Vol.38 (1), p.92-98

2004

Volltextzugriff (PDF)

In Vitro Activities of Daptomycin, Vancomycin, Linezolid, and Quinupristin-Dalfopristin against Staphylococci and Enterococci, Including Vancomycin- Intermediate and -Resistant Strains

Antimicrobial Agents and Chemotherapy, 2000-04, Vol.44 (4), p.1062-1066

2000

Volltextzugriff (PDF)

Relationship between Fluoroquinolone Use and Changes in Susceptibility to Fluoroquinolones of Selected Pathogens in 10 United States Teaching Hospitals, 1991–2000

Clinical infectious diseases, 2003-12, Vol.37 (12), p.1643-1648

2003

Volltextzugriff (PDF)

Epidemiology of antimicrobial resistance in enterococci of animal origin

Journal of antimicrobial chemotherapy, 2005-01, Vol.55 (1), p.127-130

2005

Volltextzugriff (PDF)

Impact of Renal Function on the Pharmacokinetics and Safety of Ceftolozane-Tazobactam

Antimicrobial agents and chemotherapy, 2014-04, Vol.58 (4), p.2249-2255

2014

Volltextzugriff (PDF)

Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections

Antimicrobial agents and chemotherapy, 2014-09, Vol.58 (9), p.5350-5357

2014

Volltextzugriff (PDF)

Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials

Journal of antimicrobial chemotherapy, 2017-01, Vol.72 (1), p.268-272

2017

Volltextzugriff (PDF)

Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections

Journal of clinical pharmacology, 2015-02, Vol.55 (2), p.230-239

2015

Volltextzugriff (PDF)

Characteristics and Outcomes of Complicated Intra-abdominal Infections Involving Pseudomonas aeruginosa from a Randomized, Double-Blind, Phase 3 Ceftolozane-Tazobactam Study

Antimicrobial agents and chemotherapy, 2016-07, Vol.60 (7), p.4387-4390

2016

Volltextzugriff (PDF)

Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: Results from a randomized, double-blind, phase-2, placebo-controlled study

EBioMedicine, 2019-02, Vol.40, p.574-582

2019

Volltextzugriff (PDF)

583: IMPACT OF NONSTUDY ANTIBIOTICS IN THE COMBATING ANTIBIOTIC-RESISTANT ENTEROBACTERIACEAE (CARE) STUDY

Critical care medicine, 2019-01, Vol.47 (1), p.272-272

2019

Volltextzugriff (PDF)

Response to Spellberg and Brass

Clinical infectious diseases, 2016-02, Vol.62 (4), p.526-526

2016

Volltextzugriff (PDF)

Activities of LY333328 and Vancomycin Administered Alone or in Combination with Gentamicin against Three Strains of Vancomycin-Intermediate Staphylococcus aureus in an In Vitro Pharmacodynamic Infection Model

Antimicrobial Agents and Chemotherapy, 2000-11, Vol.44 (11), p.2991-2998

2000

Volltextzugriff (PDF)

Daptomycin for Pediatric Gram-Positive Acute Hematogenous Osteomyelitis

The Pediatric infectious disease journal, 2020-09, Vol.39 (9), p.814-823

2020

Volltextzugriff (PDF)

Analysis of Vancomycin Population Susceptibility Profiles, Killing Activity, and Postantibiotic Effect against Vancomycin-Intermediate Staphylococcus aureus

Antimicrobial Agents and Chemotherapy, 1999-08, Vol.43 (8), p.1914-1918

1999

Volltextzugriff (PDF)

Activities of Trovafloxacin, Gatifloxacin, Clinafloxacin, Sparfloxacin, Levofloxacin, and Ciprofloxacin against Penicillin-Resistant Streptococcus pneumoniae in an In Vitro Infection Model

Antimicrobial Agents and Chemotherapy, 2000-03, Vol.44 (3), p.598-601

2000

Volltextzugriff (PDF)

Safety and clinical outcomes among older adults receiving daptomycin therapy: Insights from a patient registry

The American journal of geriatric pharmacotherapy, 2010-12, Vol.8 (6), p.551-561

2010

Volltextzugriff (PDF)

Evaluation of Bactericidal Activities of LY333328, Vancomycin, Teicoplanin, Ampicillin-Sulbactam, Trovafloxacin, and RP59500 Alone or in Combination with Rifampin or Gentamicin against Different Strains of Vancomycin-Intermediate Staphylococcus aureus by Time-Kill Curve Methods

Antimicrobial Agents and Chemotherapy, 1999-03, Vol.43 (3), p.717-721

1999

Volltextzugriff (PDF)

1132. Integrated Quantitative Systems Pharmacology (QSP) Characterizing Viral Dynamics After Intramuscular (IM) Adintrevimab (ADI) Administration in Participants with Mild to Moderate Coronavirus Disease (COVID-19)

Open forum infectious diseases, 2022-12, Vol.9 (Supplement_2)

2022

Volltextzugriff (PDF)

Comparison of a Rabbit Model of Bacterial Endocarditis and an In Vitro Infection Model with Simulated Endocardial Vegetations

Antimicrobial Agents and Chemotherapy, 2000-07, Vol.44 (7), p.1921-1924

2000

Volltextzugriff (PDF)

633. Preliminary Results from a Phase 1 Single Ascending-Dose Study Assessing Safety, Serum Viral Neutralizing Antibody Titers (sVNA), and Pharmacokinetic (PK) Profile of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Treatment and Prevention of Coronavirus Disease (COVID-19)

Open forum infectious diseases, 2021-12, Vol.8 (Supplement_1), p.S420-S420

2021

Volltextzugriff (PDF)

1 – 25 von 51

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(49)
Mit Volltextzugriff
(44)

Publikationsform

Artikel
(51)

Sprache

Englisch
(51)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(33)
Science & Technology
(33)
Microbiology
(25)
Humans
(23)
Biological And Medical Sciences
(21)
Pharmacology & Pharmacy
(20)
Medical Sciences
(16)
Pharmacology. Drug Treatments
(16)
Infectious Diseases
(15)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(14)
Female
(13)
Male
(12)
Microbial Sensitivity Tests
(11)
Anti-Bacterial Agents - Pharmacology
(10)
Antibacterial Agents
(10)
Aged
(9)
Middle Aged
(9)
Staphylococcus Aureus
(9)
Adult
(8)
Immunology
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)

Pharmacokinetics and Safety of Intravenous Ceftolozane-Tazobactam in Healthy Adult Subjects following Single and Multiple Ascending Doses

Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy

Thrombocytopenia Associated with Linezolid Therapy

Quinupristin-Dalfopristin Resistance in Gram-Positive Bacteria: Mechanism of Resistance and Epidemiology

In Vitro Activities of Daptomycin, Vancomycin, Linezolid, and Quinupristin-Dalfopristin against Staphylococci and Enterococci, Including Vancomycin- Intermediate and -Resistant Strains

Relationship between Fluoroquinolone Use and Changes in Susceptibility to Fluoroquinolones of Selected Pathogens in 10 United States Teaching Hospitals, 1991–2000

Epidemiology of antimicrobial resistance in enterococci of animal origin

Impact of Renal Function on the Pharmacokinetics and Safety of Ceftolozane-Tazobactam

Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections

Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials

Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections

Characteristics and Outcomes of Complicated Intra-abdominal Infections Involving Pseudomonas aeruginosa from a Randomized, Double-Blind, Phase 3 Ceftolozane-Tazobactam Study

Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: Results from a randomized, double-blind, phase-2, placebo-controlled study

583: IMPACT OF NONSTUDY ANTIBIOTICS IN THE COMBATING ANTIBIOTIC-RESISTANT ENTEROBACTERIACEAE (CARE) STUDY

Response to Spellberg and Brass

Activities of LY333328 and Vancomycin Administered Alone or in Combination with Gentamicin against Three Strains of Vancomycin-Intermediate Staphylococcus aureus in an In Vitro Pharmacodynamic Infection Model

Daptomycin for Pediatric Gram-Positive Acute Hematogenous Osteomyelitis

Analysis of Vancomycin Population Susceptibility Profiles, Killing Activity, and Postantibiotic Effect against Vancomycin-Intermediate Staphylococcus aureus

Activities of Trovafloxacin, Gatifloxacin, Clinafloxacin, Sparfloxacin, Levofloxacin, and Ciprofloxacin against Penicillin-Resistant Streptococcus pneumoniae in an In Vitro Infection Model

Safety and clinical outcomes among older adults receiving daptomycin therapy: Insights from a patient registry

Evaluation of Bactericidal Activities of LY333328, Vancomycin, Teicoplanin, Ampicillin-Sulbactam, Trovafloxacin, and RP59500 Alone or in Combination with Rifampin or Gentamicin against Different Strains of Vancomycin-Intermediate Staphylococcus aureus by Time-Kill Curve Methods

1132. Integrated Quantitative Systems Pharmacology (QSP) Characterizing Viral Dynamics After Intramuscular (IM) Adintrevimab (ADI) Administration in Participants with Mild to Moderate Coronavirus Disease (COVID-19)

Comparison of a Rabbit Model of Bacterial Endocarditis and an In Vitro Infection Model with Simulated Endocardial Vegetations

Suchergebnisse filtern